Asia Begins To See Impact From Roche 'De-Siloing'

As part of a global strategy first unveiled last year, Roche is taking concrete steps to restructure its pharma operations in Asia, including the substantial downsizing of a Singapore office.

Singapore Garden Bay
Singapore Affected In Roche Asia Restructuring • Source: Shutterstock

Roche is now in the implementation stage of a worldwide reorganization program first disclosed last year, which in Asia has so far meant the rationalization of one regional office, among other structural and personnel changes.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By 

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By 

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By 

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By 

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

More from Business

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By 

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By 

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.